GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Additional Paid-In Capital

argenx SE (argenx SE) Additional Paid-In Capital : $5,651 Mil(As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Additional Paid-In Capital?


argenx SE's quarterly additional paid-in capital declined from Jun. 2023 ($4,374 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($5,651 Mil).

argenx SE's annual additional paid-in capital increased from Dec. 2021 ($3,463 Mil) to Dec. 2022 ($4,310 Mil) and increased from Dec. 2022 ($4,310 Mil) to Dec. 2023 ($5,651 Mil).

argenx SE Additional Paid-In Capital Historical Data

The historical data trend for argenx SE's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Additional Paid-In Capital Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,505.64 2,339.03 3,462.78 4,309.88 5,651.50

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,309.88 - 4,374.29 - 5,651.50

argenx SE Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

argenx SE Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of argenx SE's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Additional Paid-In Capital
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.